---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-046134"
form_type: "8-K"
ticker: null
cik: "0001178879"
company_name: "AMICUS THERAPEUTICS, INC."
filed_at: "2025-12-19T23:59:59+00:00"
generated_at: "2026-05-16T12:31:39.290465+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Amicus agrees to be acquired by BioMarin for $14.50 per share in cash

## Summary
- Merger consideration $14.50 per share; expected to close in Q2 2026.
- Termination fee of $175M payable by Amicus in certain termination scenarios.
- Transaction requires shareholder approval, HSR and foreign antitrust clearances.
- No-solicit restrictions apply; Amicus board may consider superior proposals under fiduciary duty.
- Bylaws amended to add exclusive forum provision (Item 5.03).

## SEC filing metadata
- accession: 0001140361-25-046134
- form_type: 8-K
- cik: 0001178879
- company_name: AMICUS THERAPEUTICS, INC.
- filed_at: 2025-12-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/0001140361-25-046134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/ef20061157_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-046134
- JSON: https://secwatch.observer/filing/0001140361-25-046134.json
- Plain text: https://secwatch.observer/filing/0001140361-25-046134.txt

## Key facts
- Governance Changes
  AMICUS THERAPEUTICS, INC.: On December 19, 2025, the Board approved and adopted a Forum Selection Amendment to the Company's existing By-laws, adding a new Section 6.5 to Article VI (effective 2025-12-19).
  - Change: bylaw amendment
  - Effective: 2025-12-19
  source text: On December 19, 2025, the Board approved and adopted an amendment (the “ Forum Selection Amendment ”) to the Company’s existing By-laws that amends Article VI to include a new Section 6.5.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/0001140361-25-046134-index.htm
- Material Agreements
  AMICUS THERAPEUTICS, INC. entered into Agreement and Plan of Merger with BioMarin Pharmaceutical Inc. valued at $14.50 per Share in cash (effective 2025-12-19).
  - Action: entry
  - Agreement: merger
  - Counterparty: BioMarin Pharmaceutical Inc.
  - Value: $14.50 per Share in cash
  - Effective: 2025-12-19
  source text: On December 19, 2025, Amicus Therapeutics, Inc. (the “ Company ” or “ Amicus ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with BioMarin Pharmaceutical Inc., a Delaware corporation (“ Parent ”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ Merger Sub ”), providing for the merger of Merger Sub with and into the Company (the “ Merger ”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/0001140361-25-046134-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.